Medicine guide
Rasitrio
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Aliskiren;amlodipine;hydrochlorothiazide
- Made by
- Novartis Europharm Ltd.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Novartis Europharm Ltd. |
|---|---|
| Active substance | Aliskiren;amlodipine;hydrochlorothiazide |
| Used in | Heart, blood pressure and circulation |
| Classification | C09XA54 · Heart, blood pressure and circulation |
| Authorised on | 2011-11-22 |
| Last updated by the regulator | 2012-09-20 |
| EMA product number | EMEA/H/C/002017 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).